Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ESPR
CUSIPN/A
Phone734-887-3903
Debt
Debt-to-Equity RatioN/A
Current Ratio6.70
Quick Ratio6.70
Price-To-Earnings
Trailing P/E Ratio-6.07
Forward P/E Ratio-6.68
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$9.34 per share
Price / Book4.52
Profitability
EPS (Most Recent Fiscal Year)($6.98)
Net Income$-166,980,000.00
Net MarginsN/A
Return on Equity-77.47%
Return on Assets-67.65%
Miscellaneous
Employees57
Outstanding Shares26,790,000
Market Cap$1,134.39
Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions
What is Esperion Therapeutics' stock symbol?
Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."
How were Esperion Therapeutics' earnings last quarter?
Esperion Therapeutics Inc (NASDAQ:ESPR) posted its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($1.56) by $0.17. During the same period in the previous year, the firm posted ($1.80) earnings per share. View Esperion Therapeutics' Earnings History.
When is Esperion Therapeutics' next earnings date?
What price target have analysts set for ESPR?
13 analysts have issued twelve-month price objectives for Esperion Therapeutics' stock. Their predictions range from $41.00 to $153.00. On average, they expect Esperion Therapeutics' stock price to reach $89.0769 in the next twelve months. This suggests a possible upside of 111.4% from the stock's current price. View Analyst Ratings for Esperion Therapeutics.
What is the consensus analysts' recommendation for Esperion Therapeutics?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Esperion Therapeutics stock?
Here are some recent quotes from research analysts about Esperion Therapeutics stock:
- 1. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (7/10/2018)
- 2. Chardan Capital analysts commented, "We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe (BA+eze) fixed dose combo (FDC) has been confirmed by the FDA. A definition of statin intolerance has also been agreed on by the FDA. KOLs (e.g. Dr. Nissen) support the need for therapies for patients who are (or believe themselves to be) statin intolerant and refuse statins. CANTOS suggests BA’s high-sensitivity C-reactive protein (hsCRP) lowering effect is highly relevant for CV event reduction and outcomes. Newly-disclosed integrated phase II results suggest sound BA safety. A larger market opportunity results from a pivotal BA phase III design that includes patients “on any statin dose.” Limited use of PCSK9 inhibitors, due to pricing, opens an opportunity. Merck’s (unrated) decision not to file anacetrapib for approval further confirms oral CETP inhibitors as uninteresting assets or competitors." (12/5/2017)
Who are some of Esperion Therapeutics' key competitors?
Some companies that are related to Esperion Therapeutics include Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), The Medicines (MDCO), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Intercept Pharmaceuticals (ICPT), Horizon Pharma (HZNP), Heron Therapeutics (HRTX) and Emergent Biosolutions (EBS).
Who are Esperion Therapeutics' key executives?
Esperion Therapeutics' management team includes the folowing people:
- Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 57)
- Dr. Narendra D. Lalwani, Exec. VP of R&D and COO (Age 65)
- Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 36)
- Ms. Marianne Andreach, Sr. VP of Product Planning
- Ms. Ashley Hall, Sr. VP of Global Regulatory Affairs and Policy
Has Esperion Therapeutics been receiving favorable news coverage?
Media headlines about ESPR stock have trended somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Esperion Therapeutics earned a coverage optimism score of 0.05 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.47 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Esperion Therapeutics' major shareholders?
Esperion Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.63%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Narendra D Lalwani, Nicole Vitullo, Roger S Newton and Target N V Biotech. View Institutional Ownership Trends for Esperion Therapeutics.
Which institutional investors are selling Esperion Therapeutics stock?
ESPR stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold Esperion Therapeutics company stock in the last year include Nicole Vitullo and Roger S Newton. View Insider Buying and Selling for Esperion Therapeutics.
How do I buy shares of Esperion Therapeutics?
Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Esperion Therapeutics' stock price today?
One share of ESPR stock can currently be purchased for approximately $42.13.
How big of a company is Esperion Therapeutics?
Esperion Therapeutics has a market capitalization of $1.13 billion. The biopharmaceutical company earns $-166,980,000.00 in net income (profit) each year or ($6.98) on an earnings per share basis. Esperion Therapeutics employs 57 workers across the globe.
How can I contact Esperion Therapeutics?
Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]
MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
